Trial
NCT04459715
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
GORTEC (Head and Neck Oncology and Radiotherapy Group); Merck KGaA, Darmstadt, Germany
Condition
Squamous Cell Carcinoma of the Head and Neck
Intervention
Xevinapant (Debio 1143)
Why stopped
Study has crossed the pre-defined futility boundary at the Interim Analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-08